{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:33:58Z","timestamp":1790876038630,"version":"4.1.0"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:00:00Z","timestamp":1684281600000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.ejca.2023.01.031","type":"journal-article","created":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T16:35:49Z","timestamp":1676392549000},"page":"39-47","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":112,"special_numbering":"C","title":["OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer"],"prefix":"10.1016","volume":"184","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3109-1692","authenticated-orcid":false,"given":"Mark E.","family":"Robson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seock-Ah","family":"Im","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elzbieta","family":"Senkus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binghe","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Domchek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norikazu","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzette","family":"Delaloge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Tung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0774-7006","authenticated-orcid":false,"given":"Anne","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5981-391X","authenticated-orcid":false,"given":"Mike","family":"Dymond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anitra","family":"Fielding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5210-5344","authenticated-orcid":false,"given":"Pierfranco","family":"Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2023.01.031_bib1","doi-asserted-by":"crossref","first-page":"8297","DOI":"10.1158\/0008-5472.CAN-06-0503","article-title":"Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years","volume":"66","author":"Malone","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2023.01.031_bib2","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1158\/1055-9965.EPI-08-1090","article-title":"Performance of prediction models for BRCA mutation carriage in three racial\/ethnic groups: findings from the Northern California Breast Cancer Family Registry","volume":"18","author":"Kurian","year":"2009","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"10.1016\/j.ejca.2023.01.031_bib3","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1093\/annonc\/mdw209","article-title":"Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic","volume":"27","author":"Winter","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2023.01.031_bib4","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1200\/JCO.2014.57.1414","article-title":"Inherited mutations in 17 breast cancer susceptibility genes\u00a0among a large triple-negative breast cancer cohort unselected for family history of breast cancer","volume":"33","author":"Couch","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.01.031_bib5","doi-asserted-by":"crossref","first-page":"301","DOI":"10.4048\/jbc.2014.17.4.301","article-title":"Unique features of young age breast cancer and its management","volume":"17","author":"Lee","year":"2014","journal-title":"J Breast Cancer"},{"key":"10.1016\/j.ejca.2023.01.031_bib6","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s10549-016-3697-z","article-title":"Low prevalence of HER2 positivity amongst BRCA1 and BRCA2 mutation carriers and in primary BRCA screens","volume":"155","author":"Evans","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2023.01.031_bib7","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with\u00a0a\u00a0germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.01.031_bib8","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ejca.2019.06.023","article-title":"Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial","volume":"120","author":"Robson","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.01.031_bib9","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/annonc\/mdz012","article-title":"OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","volume":"30","author":"Robson","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2023.01.031_bib10","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/s41416-018-0271-y","article-title":"Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy","volume":"119","author":"Friedlander","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2023.01.031_bib11","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/j.annonc.2020.08.2098","article-title":"Talazoparib versus chemotherapy in patients with germline BRCA1\/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial","volume":"31","author":"Litton","year":"2020","journal-title":"Ann Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923000801?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923000801?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:39:36Z","timestamp":1760733576000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804923000801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":11,"alternative-id":["S0959804923000801"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.01.031","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.01.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}